For example, the “Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes” trial (NCT02964585) is currently recruiting patients with T2DM to study, as the primary endpoint, the gene expression and functional changes of CD34+ EPC. The gene discussed is CD34; the disease is type 2 diabetes mellitus.